The U.S. Food and Drug Administration in 2010 issued a Plavix warning label to reflect that information. Bristol Myers and Sanofi faced a similar lawsuit from New Mexico, which settled in 2022.

Bristol-Myers Squibb Co. and Sanofi were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blockbuster blood-thinning drug Plavix in a manner that put some ...

PARIS, Jan 18 (Reuters) - The odds on Sanofi-Aventis saving its patent on blockbuster Plavix from generic rivalry in the United States have improved, freeing the French drugmaker's hand for ...

In a release, Bristol BMY and Sanofi SNY said that they have struck a deal with Canadian drugmaker Apotex, who had been suing to have Plavix's patents declared invalid in order to pave the way for ...

File this under 'Why didn't they know any better?' Four years ago, Sanofi (SNY) grew worried that a generic version of its best-selling Plavix blood thinner would gain attention from physicians ...

France’s antitrust authority has fined Sanofi €40.6m ($53m) for telling doctors that generic copies of its blockbuster antiplatelet drug Plavix (clopidogrel) were not suitable substitutes for its own ...

Sanofi-Aventis and Bristol-Myers Squibb Co. said they had settled a dispute with generic drug maker Apotex Inc. that could keep patent protection on their multibillion-dollar blood thinner Plavix ...

Sanofi-Aventis, and the Medicines Company; and having provided expert testimony regarding clopidogrel (the compensation was donated to a nonprofit organization). Dr. Fox reports having received ...

French drug maker Sanofi-Aventis SA warned that generic copies of the blood-thinner Plavix already on the market would undermine 2006 profit, as investors criticized Sanofi and partner Bristol ...

Bristol-Myers Squibb Co. and Sanofi were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blockbuster blood-thinning drug Plavix in a manner that put some ...